For complex and high-profile patent and IP actions, such as Hatch-Waxman (ANDA) litigations, numerous Fortune 500 companies have trusted Ryan with their cases. Ryan has litigated a broad range of intellectual property (IP) cases, including litigations over “blockbuster” pharmaceutical products with global sales exceeding $1 billion per year and bet-the-company gaming litigations involving a blend of IP and contract issues. His complex patent litigation experience includes multidistrict litigations (MDL), Hatch-Waxman (ANDA) litigations, and unfair import investigations (section 337 patent infringement actions) in the U.S. International Trade Commission. Ryan has also handled high-stakes trademark and trade secret litigation.
Prior to joining the firm, Ryan practiced intellectual property law at Watson Rounds, a firm Brownstein merged with September 1, 2015, Finnegan Henderson in Washington, D.C., and Fitzpatrick Cella in New York, NY. Prior to law school, he worked as a high school teacher and varsity lacrosse and soccer coach.
Represented NewDay Financial in a declaratory judgment action against United Services Automobile Association (“USAA”) in the District of Maryland involving USAA’s allegations of copyright and trademark infringement. A motion to dismiss USAA’s first-filed complaint in the Northern District of Texas was granted for lack of personal jurisdiction. Case settled
Represented Galaxy Gaming in an AAA arbitration proceeding regarding Galaxy’s table game High Card Flush. Prevailed on issues of intellectual property ownership, willful infringement, fraud, permanent injunction, and attorneys’ fees.
Aervoe Indus., Inc. v. PMG, Inc., No. 3:14-cv-00488 (D. Nev. 2014) (declaratory judgment action for patent noninfringement and patent invalidity).
Walker Digital Table Systems, LLC v. GPI Corp., No. 2:14-cv-00438 (D. Nev. 2014) (patent litigation regarding phase jitter modulation RFID technology).
Counseled Walker Digital Table Systems, LLC regarding various business and patent licensing issues.
In the Matter of Certain Gemcitabine and Products Containing the Same, Inv. No. 337-TA-766 (U.S. ITC) (unfair import investigation).
Eli Lilly and Co. v. Sicor Pharm., Inc., 705 F. Supp. 2d 971 (S.D. Ind. 2010) (ANDA litigation regarding Gemzar®).
Adams Respiratory Therapeutics, Inc. v. Pharmaceutical Holdings Corp., No. 06-cv-4418 (E.D. Pa.) (ANDA litigation regarding Mucinex®).
Astellas Pharma, Inc. v. Ranbaxy, Inc., No. 05-cv-2563, 2007 WL 576341 (D.N.J. Feb. 21, 2007) (ANDA litigation regarding Flomax®).
Merck and Co. v. Dr. Reddy’s Lab. Ltd., No. 04-cv-1313 (D. Del.) (ANDA litigation regarding Propecia®).
In re Omeprazole Patent Litigation, MDL Docket No. 1291, Master Docket No. M-21-81 (S.D.N.Y.) (ANDA litigation regarding Prilosec®).
In re Gabapentin Patent Litigation, MDL Docket No. 1384, Master Docket No. 00-cv-2931 (D.N.J.) (ANDA litigation regarding Neurontin®).
Gaming Patents And “Abstract Ideas”: What Are The Rules Of The Game?Co-author, CGi Magazine, May 2019
Mobile Gambling and the Implications of American Broadcasting Company, Inc. v. Aereo, Inc.Author, Nevada Business Magazine, November 2014
A Cross-Appeal Is Improper When It Would Not Expand the Scope of a District Court Judgment in Favor of the Cross-AppellantAuthor, Last Month at the Federal Circuit, April 2011
Dismissal of Plaintiff’s DJ Complaint for Lack of Personal Jurisdiction over Defendants ReversedAuthor, Last Month at the Federal Circuit, October 2008
American Bar Association
American Intellectual Property Association